A TWO-SITE IMMUNOASSAY WILL BE DEVELOPED AGAINST APOLIPO- PROTEIN A-I (APOA-I), THE MAJOR APOPROTEIN OF HIGH-DENSITY LIPOPROTEIN (HDL).

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 5000
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1986
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Solomon Park Research Labs
12815 Ne 124th Street, Kirkland, WA, 98304
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 PATRIC A CLAPSHAW
 PRINCIPAL INVESTIGATOR
 (206) 821-7005
Business Contact
Phone: () -
Research Institution
N/A
Abstract
A TWO-SITE IMMUNOASSAY WILL BE DEVELOPED AGAINST APOLIPO- PROTEIN A-I (APOA-I), THE MAJOR APOPROTEIN OF HIGH-DENSITY LIPOPROTEIN (HDL). LOW LEVELS OF APOA-I HAVE BEEN POSITIVELY CORRELATED WITH CORONARY ARTERY DISEASE (CAD). TO ENSURE ADEQUATE QUANTIFICATION, CYANOGEN BROMIDE (CNBR) FRAGMENTS OF APOA-I WILL BE USED TO GENERATE MONOCLONAL ANTIBODIES (MABS), WHICH WILL BE SELECTED TO RECOGNIZE SEPARATE EPITOPES ON THE SOLUBLE PROTEIN IN UNTREATED PLASMA. THE ASSAY SYSTEM USED WILL BE THE ENZYME-LINKED IMMUNOSORBANT ASSAY (ELISA). QUANTITATIVE RESULTS FROM THE ELISA WILL BE CORRELATED WITH OTHER IMMUNOASSAYS AND WITH ASSAYS BASED ON DIRECT MEASUREMENT OF PROTEIN MASS. THE ULTIMATE GOAL WILL BE TO DEVELOP ELISA KITS FOR RESEARCH ANDCLINICAL MEASUREMENT OF THIS IMPORTANT CAD RISK FACTOR.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government